High‐dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia

In this national study, we have evaluated a new intensive chemotherapy protocol for adult patients with untreated acute lymphoblastic leukaemia (ALL). One hundred and fifty‐three patients with median age 42 years received induction therapy with high‐dose cytarabine (Ara‐C), cyclophosphamide, daunoru...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2002-09, Vol.118 (3), p.748-754
Main Authors: Hallböök, Helene, Simonsson, Bengt, Ahlgren, Thomas, Björkholm, Magnus, Carneskog, Jan, Grimfors, Gunnar, Hast, Robert, Karlsson, Karin, Kimby, Eva, Lerner, Richard, Linder, Olle, Linderholm, Mats, Löfvenberg, Eva, Malm, Claes, Nilsson, Per‐Gunnar, Paul, Christer, Stenke, Leif, Stockelberg, Dick, Tidefelt, Ulf, Turesson, Ingemar, Uden‐Blome, Ann‐Marie, Vilen, Lars, Wahlin, Anders, Winquist, Ingemar, Smedmyr, Bengt
Format: Article
Language:English
Subjects:
acute lymphoblastic leukaemia
Adolescent
Adult
adults
Age Factors
Aged
Aged, 80 and over
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Chemotherapy
Cytarabine - administration & dosage
Disease-Free Survival
Drug Administration Schedule
Female
Hematology
Hematopoietic Stem Cell Transplantation
high‐dose Ara‐C
Humans
Immunophenotyping
Male
Medical sciences
MEDICIN
Medicin och hälsovetenskap
MEDICINE
Middle Aged
Pharmacology. Drug treatments
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - immunology
Remission Induction
Risk Factors
Survival Rate
transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this national study, we have evaluated a new intensive chemotherapy protocol for adult patients with untreated acute lymphoblastic leukaemia (ALL). One hundred and fifty‐three patients with median age 42 years received induction therapy with high‐dose cytarabine (Ara‐C), cyclophosphamide, daunorubicin, vincristine and betamethasone. A high complete remission (CR) rate (90%) was achieved in patients  60 years (P = 0·004). The estimated 3 year overall survival for all patients was 29% (CI 21–36%) and the estimated continuous complete remission (CCR) at 3 years for the patients achieving CR according to the protocol was 36% (CI 27–45%). A favourable pretreatment characteristic was pre‐B phenotype, especially for patients
ISSN:0007-1048
1365-2141
1365-2141
DOI:10.1046/j.1365-2141.2002.03685.x